A recently identified bacterial protein structure is contributing to the design of novel anticancer drug delivery systems.

Alnylam’s drug, vutrisiran, was approved for patients with transthyretin amyloid cardiomyopathy, or ATTR-CM, to reduce ...

A study by the Neuropsychopharmacology and IBeA groups of the University of the Basque Country (UPV/EHU) paves the way to ...

During a health-focused event in New York on Tuesday, Google announced the development of a new collection of “open” AI ...

A pair of privately-held developers of editing-based therapies have some successes to show for their recent efforts to ...

To Novartis, fresh late-stage data support the idea that its intrathecal drug, which has the same active ingredient as ...

Monte Rosa announced clinical results from its MRT-6160 Phase 1, single ascending dose / multiple ascending dose study. Details about the ...

Chronic metabolic diseases with increasing prevalence and morbidity have posed serious challenges to the global healthcare ...

The explosion of GLP-1 weight loss drugs is reminiscent of the early days of PD-1 inhibitors, but key market differences ...

INmune Bio's high-upside potential with CORDStrom for RDEB and XPro for Alzheimer's, offering up to 144.8x returns. Click ...